ArticleEuropean thyroid journal2026
Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Levothyroxine titration is essential in low-risk differentiated thyroid cancer (DTC). Objective: To compare levothyroxine treatment adequacy, response distribution, and determinants of inadequacy in a large real-world cohort applying the 2015 versus 2025 American Thyroid Association (ATA) criteria. Methods: We conducted a multicenter, retrospective cohort study including 1,016 adults with low-risk DTC (median follow-up: 79 months). Dynamic risk stratification and levothyroxine treatment adequacy - defined according to framework-specific thyrotropin (TSH) targets - were assessed at 12 months and at the last visit. Secondary outcomes included rates of overtreatment and undertreatment. Multivariable logistic regression identified factors associated with adequacy among excellent or indeterminate responders. Results: Under the ATA-2025 criteria, the proportion of patients with an excellent response increased to 72.0% at 12 months and 86.9% at last visit, compared with 62.3 and 77.8% using the ATA-2015 criteria. Treatment adequacy changed from 26.0% at 12 months and 39.6% at the last follow-up visit with ATA-2015 to 40.7 and 67.4% with ATA-2025 (both P < 0.001). Under ATA-2015, inadequacy was driven by overtreatment among excellent responders (61.8% at 12 months; 30.5% at final evaluation) and undertreatment among indeterminate responders (48.4%; 62.2%). Applying the ATA-2025 criteria reclassified overtreated excellent responders as 51.9 and 25.5% and undertreated indeterminate responders as 6.6 and 8.8%, respectively. At the last visit, older age modestly favored adequacy (OR: 1.02 per year, 1.00-1.03) and levothyroxine dose instability strongly predicted inadequacy (OR: 0.12 for adequacy, 0.08-0.16). Conclusion: Applying the ATA-2025 criteria increases the proportion of patients classified as having adequate TSH control and decreases the proportion labeled as over- or undertreated under the 2015 framework, reflecting the broader, risk-adapted TSH targets introduced in 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.